Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 21 strange trades.

Benzinga

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 10 strange trades.

Benzinga

Eli Lilly Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 15 strange trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Whale Trades For August 11

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Another reason not to work in Indiana

Eli Lilly and Co. was quick to understand just how bad a near abortion ban can be on business.

Chicago Sun-Times

Eli Lilly says Indiana abortion law forces hiring out-of-state

Eli Lilly & Co., one of Indiana’s largest employers, said the state’s freshly passed restrictions on abortion would force the drugmaker to “plan for more employment growth outside our home state.”

Tribune News Service

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Accenture And 3 Other Stocks Insiders Are Selling

Johnson & Johnson (NYSE: JNJ) reported upbeat earnings for its second quarter, but lowered its FY22 guidance. Investors, meanwhile, focused on some notable insider trades.

Benzinga

2 Biotech Stocks Crushing It During the Market Crash

The Biotech industry has gained significant momentum since the pandemic. Moreover, the industry’s prospects look bright amid the lucrative federal funding and solid investments in breakthrough developments. Thus, given the stock market volatility, it could be wise to invest in quality biotech stocks Eli Lilly (LLY) and Jazz Pharmaceuticals (JAZZ),…

StockNews.com

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 14 strange trades.

Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 21.93% on an annualized basis producing an average annual return of 31.32%. Currently, Eli Lilly has a market capitalization of $307.03 billion.

Benzinga

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Executives Sell More Than $67M Of 5 Stocks: NetApp, Eli Lilly And More

US gold futures traded lower on Friday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

This Is What Whales Are Betting On Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 17 strange trades.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

LLY's New Drug Lineup Looks Promising For Investors

Eli Lilly and Company’s (LLY) new drug line-up is expected to generate higher revenues and earnings. Also, LLY’s robust earnings, favorable analyst estimates, and higher-than-industry profitability make it a promising investment option. Read on….

The Independent UK

About 4,000 women with breast cancer could benefit from new twice-daily pill

The drug, made by Eli Lilly, is suitable for those with hormone receptor-positive, HER2-negative, node-positive early breast cancer.

Benzinga

Peering Into Eli Lilly's Recent Short Interest

Eli Lilly's (NYSE:LLY) short percent of float has risen 4.76% since its last report. The company recently reported that it has 5.23 million shares sold short, which is 0.66% of all regular shares that are available for trading.

Benzinga

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,000 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 5.21% on an annualized basis producing an average annual return of 11.42%. Currently, Eli Lilly has a market capitalization of $273.33 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 35 strange trades.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

Benzinga

Executives Sell Over $100M Of 4 Stocks

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Executives Sell Around $207M Of 5 Stocks

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

What 7 Analyst Ratings Have To Say About Eli Lilly

Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter:

Benzinga

Why Eli Lilly Shares Are Rising Today

Eli Lilly And Co (NYSE: LLY) shares are trading higher by 3.58% at $296.48 after the company announced the CHMP has issued a positive opinion for OLUMIANT for the treatment of adults with severe alopecia areata.

Benzinga

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ:FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The FDA initiated the partial clinical hold following the report of a recent death that occurred in a subject with potential differentiation syndrome. Differentiation…

1 … 23 24 25 26

People

Donald Trump

157,515 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.